Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Transperitoneal Laparoscopic Adrenalectomy with a 5-year Follow-up
Overview
Affiliations
Objective: To test if posterior retroperitoneoscopic adrenalectomy (PRA) is superior to lateral transperitoneal laparoscopic adrenalectomy (LTLA).
Background: Most popular LTLA has been recently challenged by an increasing popularity of PRA, which is believed by many surgeons (not evidence-based) as superior to LTLA in the treatment of small and benign adrenal tumors.
Methods: Participants were assigned randomly to PRA or LTLA and followed for 5 years after surgery. The primary endpoint was the duration of surgery. Secondary endpoints were blood loss, conversion rate, postoperative recovery, morbidity, and costs.
Results: Sixty-five patients were included, of whom 61 (PRA 30, LTLA 31) completed the 5-year follow-up. The following differences were identified in favor of PRA vs LTLA: shorter duration of surgery (50.8 vs 77.3 minutes), lower intraoperative blood loss (52.7 vs 97.8 mL), diminished pain intensity within 48 hours postoperatively, lower prevalence of shoulder-tip pain (3.0% vs 37.5%), shorter time to oral intake (4.4 vs 7.3 hours), shorter time to ambulation (6.1 vs 11.5 hours), shorter length of hospital stay, and lower cost (1728 € vs 2315 €), respectively (P<0.001 for all). No differences were noted in conversion rate or morbidity except for herniation occurring more often after LTLA than PRA (16.1% vs 0%, P=0.022) and need for hernia repair (12.9% vs 0%, P=0.050), respectively.
Conclusions: Both approaches were equally safe. However, outcomes of PRA operations were superior to LTLA in terms of shorter surgery duration, lower blood loss, lower postoperative pain, faster recovery, improved cost-effectiveness, and abolished risk of surgical access site herniation.
Registration Number: NCT01959711 (http://www.clinicaltrials.gov).
Kim K, Park D, Oh M, Chai Y, Kim H Sci Rep. 2024; 14(1):12174.
PMID: 38806567 PMC: 11133357. DOI: 10.1038/s41598-024-63105-9.
Izawa M, Takeda T, Anno T, Iwasawa T, Yasumizu Y, Tanaka N BMC Urol. 2024; 24(1):90.
PMID: 38637748 PMC: 11025189. DOI: 10.1186/s12894-024-01469-w.
van Uitert A, Chaman-Baz H, van der Wal S, Zhu X, Wijntjes J, Timmers H Surg Endosc. 2024; 38(6):3145-3155.
PMID: 38627259 PMC: 11133209. DOI: 10.1007/s00464-024-10836-5.
van de Wiel E, Mulder J, Hendriks A, Booij Liewes-Thelosen I, Zhu X, Groenewoud H World J Urol. 2024; 42(1):187.
PMID: 38517537 PMC: 10959772. DOI: 10.1007/s00345-024-04911-8.
Araujo-Castro M, Ruiz-Sanchez J, Parra Ramirez P, Martin Rojas-Marcos P, Aguilera-Saborido A, Gomez Cerezo J Endocrine. 2024; 85(2):532-544.
PMID: 38507182 DOI: 10.1007/s12020-024-03773-9.